Clinical Trials Logo

Relapsed Mantle Cell Lymphoma clinical trials

View clinical trials related to Relapsed Mantle Cell Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05471843 Recruiting - Clinical trials for Mantle Cell Lymphoma

Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Start date: September 5, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from Part 1.

NCT ID: NCT05249959 Recruiting - Clinical trials for Refractory Mantle Cell Lymphoma

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

FIL_COLUMN
Start date: April 21, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, phase 2, multicenter, open-label, single-arm study. Primary objective is to assess the efficacy of loncastuximab tesirine given as consolidation therapy after salvage immunochemotherapy in BTKi (Bruton Tyrosine Kinase inhibitors) -treated (or BTKi intolerant) R/R (Relapse or Refractory) MCL (Mantle Cell Lymphoma) patients. The sponsor of this clinical trial is Fondazione Italiana Linfomi (FIL).

NCT ID: NCT03206970 Completed - Clinical trials for Refractory Mantle Cell Lymphoma

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Start date: March 2, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of this study was to evaluate the efficacy of zanubrutinib in participants with centrally confirmed relapsed or refractory MCL.